Recent advances in hormonal contraception

Current Opinion in Obstetrics and Gynecology

Volumn 19, Issue 6, 2007, Pages 547-553

  Erkkola, Risto ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Combined oral contraceptives; Hormonal contraception; Hormonal intrauterine device; Implants; Injectables; Progestin only contraception

Indexed keywords

ANDROGEN; CYPROTERONE ACETATE; DESOGESTREL; DIENOGEST; DIENOGEST PLUS ETHINYLESTRADIOL; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ELCOMETRINE; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETONOGESTREL; GESTAGEN; GESTODENE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; MINERALOCORTICOID RECEPTOR; NANDROLONE DERIVATIVE; NORETHISTERONE; NORGESTIMATE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROGESTERONE DERIVATIVE; SPIRONOLACTONE;

ACNE; AMENORRHEA; BLEEDING; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DEVELOPED COUNTRY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG SAFETY; DRUG WITHDRAWAL; EMERGENCY CONTRACEPTION; FUNDING; HEADACHE; HEALTH CARE PERSONNEL; HEALTH SERVICE; HORMONAL CONTRACEPTION; HUMAN; INHERITANCE; MASTALGIA; MEDICAL EDUCATION; MENSTRUAL CYCLE; MULTIPLE CYCLE TREATMENT; NAUSEA; PRACTICE GUIDELINE; PREMENSTRUAL DYSPHORIC DISORDER; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SUSTAINED RELEASE PREPARATION; THROMBOEMBOLISM; THROMBOPHILIA; UNSPECIFIED SIDE EFFECT; VAGINA RING; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, CUTANEOUS; CONTRACEPTION; CONTRACEPTION, POSTCOITAL; CONTRACEPTIVE DEVICES, FEMALE; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; ESTROGENS; FEMALE; HEALTH EDUCATION; HUMANS; MENSTRUAL CYCLE; PROGESTINS; RISK ASSESSMENT; SAFETY;

EID: 36248986603     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3282f1e7b6     Document Type: Review

References (53)

1. State of World Population 2005. New York: UNFPA; 2005.
2. Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl Med J 2001; 344:1527-1535.
3. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception 2006; 73:566-570.
4. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptive. Lancet 2001; 358:1427-1429.
5. Rosing J, Tans G, Nicolaes GA, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97:233-238.
6. Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80:1816-1821.
7. Batukan C, Muderris II, Ozcelik B, Ozturk A. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecol Endocrinol 2007; 23:38-44.
8. Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drosperinone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106:492-501.
9. Dinger JC, Heinemann LAJ, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on Oral Contraceptives based on 142 475 women-years of observation. Contraception 2007; 75:344-354.
10. Oettel M, Breitbarth H, Elger W. The pharmacological profile of dienogest. Eur J Contraception Reprod Healthcare 1998; 3:1-12.
11. van Vlijmen EF, Brouwer JL, Veeger NJ, et al. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. Arch Intern Med 2007; 167:282-289. This article analyses the risks when COCs are given to women with inherited thrombophilias.
12. Loudon NB, Foxwell M, Potts DM, et al. Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cycle pill regimen. BMJ 1977; 2:487-490.
13. Thomas SL, Ellertson C. Nuisance or natural and healthy: should menstruation be optional for women? Lancet 2000; 355:922-924.
14. Anderson FD, Gibbons W, Portman D. Long-term safety of an extended-cycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial. Am J Obstet Gynecol 2006; 195:92-96.
15. Foidart J-M, Sulak PJ, Schellschmid I, et al. The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days. Contraception 2006; 73:34-40.
16. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003; 101:653-661.
17. Archer DF, Jensen JT, Johnson JV, et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006; 74:439-445.
18. Edelman AB, Gallo MF, Jensen JT, et al. Continuous or extended cycle versus cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005; (3):CD004695.
19. Audet MC, Moreau M, Koltun WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001; 285:2347-2354.
20. Smallwood GH, Meador ML, Lenihan JP, et al. Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol 2001; 98 (5 Pt 1): 799-805.
21. van den Heuvel MW, van Bragt AJM, Alnabawy AKM, Kaptein MCJ. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and oral contraceptive. Contraception 2005; 72:168-174.
22. Dieben TO, Roumen FJME, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002; 100:585-593.
23. Roumen FJME. The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trial. Contraception 2007; 75:420-429. Review of the articles written on this new administration method for contraception.
24. Johansson ED, Sitruk-Ware R. New delivery systems in contraception: vaginal rings. Am J Obstet Gynecol 2004; 190 (4 Suppl):S54-S60.
25. Erkkola R, Landgren B-M. Role of progestins in contraception. Acta Obstet Gynecol Scand 2005; 84:207-216.
26. McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception 1994; 50 (6 Suppl 1):S1-S195.
27. Conard J, Piu-Bureau G, Bahi N, et al. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception 2004; 70:437-441.
28. Rice CF, Killick SR, Dieben T, Coelingh Bennink HA. Comparison of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel 30 micrograms daily. Hum Reprod 1999; 14:982-985.
29. Benagiano G, Primiero PM. Seventy-five microgram desogestrel minipill, a new perspective in estrogen free contraception. Ann N Y Acad Sci 2003; 997:163-173.
30. Korver T, Klipping C, Heger-Mahn D, et al. Maintenance of ovulation inhibition with 75 microg desogestrel-only contraceptive pill (Cerazette) after scheduled 12 h delays in tablet intake. Contraception 2005; 71:8-13.
31. Curtis KM, Martins SL. Progestogen-only contraception and bone mineral density: a systematic review. Contraception 2006; 73:4704-4787. Describes the effects of various progestin treatments on the bone.
32. Jain J, Jakimiuk AJ, Bode FR, et al. Contraceptive efficacy and safety of DMPA-SC. Contraception 2004; 70:269-275.
33. Newton JR. New hormonal methods of contraception. Baillières Clin Obstet Gynecol 1996; 10:87-101.
34. Meirik O, Fraser IS, d'Arcancues C. Implantable contraceptives for women. Human Reprod Update 2003; 9:49-59.
35. Meckstroth KR, Darney PD. Implantable contraception. Obstet Gynecol Clin North Am 2000; 27:781-815.
36. Coukell AJ, Balfour JA. Levonorgestrel subdermal implants: a review of contraceptive efficacy and acceptability. Drugs 1988; 55:861-887.
37. Sivin I, Nash H, Waldman S. Jadelle® levonorgestrel rod implants: a summary of scientific data and lessons learned from programmatic experience. Population Council, Inc.; 2002. pp. 1-48.
38. Croxatto HB, Urbancsek J, Massai R, et al. A multicenter efficacy and safety study of a single contraceptive implant Implanon®. Human Reprod 1999; 14:976-981.
39. French RS, Guillabaud J. Mirena®: the levonorgestrel intrauterine system (20 μg/day). J Drug Eval 2003; 1:43-70.
40. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol 1982; 17:529-536.
41. Nilsson CG, Lähteenmäki PL, Luukkainen T. Ovarian function in amenorreic and menstruating users of levonorgestrel releasing intrauterine device. Fert Steril 1984; 41:52-55.
42. Barbosa I, Bakos O, Olsson SE, et al. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 1990; 42:51-66.
43. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994; 49:56-72.
44. Backman T, Rauramo I, Huhtala S, Koskenvuo M. Pregnancy during use of levonorgestrel intrauterine system. Am J Obstet Gynecol 2004; 190:50-54.
45. Backman T, Huhtala S, Blom T, et al. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nationwide study of 17,360 users. BJOG 2000; 107:335-339.
46. World Health Organization's Task Force on Long Acting Systemic Agents for Fertility Regulation. Microdose intravaginal levonorgestrel contraception: a multicenter clinical trial. I: Contraceptive efficacy and side effects. II: Expulsions and removals. III: The relation between pregnancy rate and body weight. IV: Bleeding patterns. Contraception 1990; 41:105-167.
47. Ballagh SA. Vaginal ring hormone delivery systems in contraception and menopause. Clin Obstet Gynecol 2001; 44:106-113.
48. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Task Force of Postovulatory Methods of Fertility Regulation. Lancet 1998; 352:428-433.
49. von Hertzen H, Piaggio G, Ding J, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002; 360:1803-1810.
50. Esteve JL, García R, Breto A, Llorente M. Emergency contraception in Cuba with 10mg of mifepristone. Eur J Contracept Reprod Healthcare 2007; 12:162-167.
51. Sitruk-Ware R, Small M, Kumar N, et al. Nestorone: clinical applications for contraception and HRT. Steroids 2003; 68:907-913.
52. Pei K, Xiao B, Jing X, et al. Weekly contraception with mifepristone. Contraception 2007; 75:40-44.
53. Lakha E, Ho PC, Van der Spuy ZM, et al. A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum Reprod 2007; 3 July [Epub ahead of print].